$IRME
IR-Med, Inc. Stock $irme

$irme Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223009519 Filed on March 29, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$747.0K	$1.534M	$2.877M
YoY Change	98.67%		27.53%
% of Gross Profit
Research & Development	$605.0K	$528.0K	$1.885M
YoY Change	26.83%		32.84%
% of Gross Profit
Depreciation & Amortization	$4.000K	$0.00	$10.00K
YoY Change	33.33%		100.0%
% of Gross Profit
Operating Expenses	$1.352M	$2.062M	$4.762M
YoY Change	58.5%		29.58%
Operating Profit	-$1.352M		-$4.762M
YoY Change	58.5%		29.58%
Interest Expense	$2.000K	-$28.00K	$28.00K
YoY Change			-168.29%
% of Operating Profit
Other Income/Expense, Net	$2.000K		$28.00K
YoY Change	-50.0%		-168.29%
Pretax Income	-$1.350M	-$2.090M	$4.734M
YoY Change			27.4%
Income Tax
% Of Pretax Income
Net Earnings	-$1.350M	-$2.090M	-$4.734M
YoY Change	59.01%		27.4%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.02		-$0.07
Diluted Earnings Per Share	-$0.02	-$0.03	-$0.07
COMMON SHARES
Basic Shares Outstanding	68.81M shares	68.72M shares	67.58M shares
Diluted Shares Outstanding	68.83M shares		67.58M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.103M	$3.002M	$3.002M
YoY Change			6.64%
Cash & Equivalents	$2.103M	$3.002M	$3.002M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses		$12.00K
Receivables	$56.00K	$55.00K	$55.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.159M	$3.057M	$3.057M
YoY Change		6.07%	6.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$67.00K	$71.00K	$226.0K
YoY Change		129.03%	629.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$11.00K	$11.00K	$11.00K
YoY Change			-63.33%
Total Long-Term Assets	$214.0K	$237.0K	$237.0K
YoY Change		288.52%	288.52%
TOTAL ASSETS
Total Short-Term Assets	$2.159M	$3.057M	$3.057M
Total Long-Term Assets	$214.0K	$237.0K	$237.0K
Total Assets	$2.373M	$3.294M	$3.294M
YoY Change		11.93%	11.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$468.0K	$500.0K	$151.0K
YoY Change			19.84%
Accrued Expenses		$132.0K	$299.0K
YoY Change		-5.71%	11.15%
Deferred Revenue
YoY Change
Short-Term Debt	$159.0K	$162.0K	$162.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$627.0K	$662.0K	$662.0K
YoY Change		67.59%	67.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$26.00K	$40.00K	$40.00K
YoY Change
Total Long-Term Liabilities	$26.00K	$40.00K	$40.00K
YoY Change		-77.4%	-77.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$627.0K	$662.0K	$662.0K
Total Long-Term Liabilities	$26.00K	$40.00K	$40.00K
Total Liabilities	$653.0K	$702.0K	$702.0K
YoY Change		22.73%	22.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$11.28M	-$9.930M
YoY Change		91.11%
Common Stock	$68.00K	$68.00K
YoY Change		6.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.720M	$2.592M	$2.592M
YoY Change
Total Liabilities & Shareholders Equity	$2.373M	$3.294M	$3.294M
YoY Change		11.93%	11.93%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.350M	-$2.090M	-$4.734M
YoY Change	59.01%		27.4%
Depreciation, Depletion And Amortization	$4.000K	$0.00	$10.00K
YoY Change	33.33%		100.0%
Cash From Operating Activities	-$900.0K	-$779.0K	-$3.375M
YoY Change	19.36%		35.98%
INVESTING ACTIVITIES
Capital Expenditures		$2.000K	$50.00K
YoY Change			61.29%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$9.000K
YoY Change			-70.0%
Cash From Investing Activities		-$2.000K	-$59.00K
YoY Change			-3.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	$3.625M
YoY Change			3.84%
NET CHANGE
Cash From Operating Activities	-$900.0K	-779.0K	-$3.375M
Cash From Investing Activities		-2.000K	-$59.00K
Cash From Financing Activities		0.000	$3.625M
Net Change In Cash	-$899.0K	-781.0K	$187.0K
YoY Change			-80.3%
FREE CASH FLOW
Cash From Operating Activities	-$900.0K	-$779.0K	-$3.375M
Capital Expenditures		$2.000K	$50.00K
Free Cash Flow	-$900.0K	-$781.0K	-$3.425M
YoY Change	17.65%		36.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001839133
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2021Q4	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent		usd
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations		usd
CY2022Q4	us-gaap	Due To Officers Or Stockholders Noncurrent DueToOfficersOrStockholdersNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021	IRME	Increase In Right Of Use Assets Against Lease Liability IncreaseInRightOfUseAssetsAgainstLeaseLiability		usd
CY2021	IRME	Increase In Right Of Use Assets Against Long Term Restricted Deposits IncreaseInRightOfUseAssetsAgainstLongTermRestrictedDeposits		usd
CY2022	IRME	Decrease In Trade And Other Payables From Grant Of Options DecreaseInTradeAndOtherPayablesFromGrantOfOptions		usd
CY2022Q1	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#Liabilities
CY2022Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#Liabilities
CY2021Q4	IRME	Accounts Payable Advance From Customers AccountsPayableAdvanceFromCustomers		usd
CY2021Q4	IRME	Accounts Payable Lease Liability AccountsPayableLeaseLiability		usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2021Q4	IRME	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-56492
CY2022	dei	Entity Registrant Name EntityRegistrantName	IR-MED, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0583166
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	ZHR Industrial Zone
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Rosh Pina
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	City Area Code CityAreaCode	972
CY2022	dei	Local Phone Number LocalPhoneNumber	4-655-5054
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	68808970	shares
CY2022Q2	dei	Entity Public Float EntityPublicFloat	76264209	usd
CY2022	dei	Auditor Firm AuditorFirmId	1057
CY2022	dei	Auditor Name AuditorName	Somekh Chaikin
CY2022	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3002000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2815000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	55000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	67000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	3057000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2882000	usd
CY2022Q4	IRME	Long Term Restricted Deposit LongTermRestrictedDeposit	11000	usd
CY2021Q4	IRME	Long Term Restricted Deposit LongTermRestrictedDeposit	30000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	155000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	71000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	237000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	61000	usd
CY2022Q4	us-gaap	Assets Assets	3294000	usd
CY2021Q4	us-gaap	Assets Assets	2943000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	500000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	395000	usd
CY2022Q4	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	162000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	662000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	395000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	40000	usd
CY2021Q4	us-gaap	Due To Officers Or Stockholders Noncurrent DueToOfficersOrStockholdersNoncurrent	177000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	40000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	177000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	702000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	572000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68808970	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68808970	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64601649	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64601649	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	68000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	64000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12454000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7503000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9930000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5196000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2592000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2371000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3294000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2943000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1885000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1419000	usd
CY2022	us-gaap	Marketing Expense MarketingExpense	759000	usd
CY2021	us-gaap	Marketing Expense MarketingExpense	888000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2118000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1368000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4762000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3675000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	28000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-41000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4734000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3716000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2371000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1330000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3625000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4734000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2592000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2592000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1401000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1401000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1384000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3302000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3716000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2371000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2371000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4734000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3716000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1330000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1339000	usd
CY2022	us-gaap	Depreciation Depreciation	10000	usd
CY2021	us-gaap	Depreciation Depreciation	5000	usd
CY2022	IRME	Increase Decrease In Accrued Financial Expenses IncreaseDecreaseInAccruedFinancialExpenses	28000	usd
CY2021	IRME	Increase Decrease In Accrued Financial Expenses IncreaseDecreaseInAccruedFinancialExpenses	-11000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	38000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	35000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-83000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3375000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2482000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	50000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	usd
CY2022	IRME	Increase In Long Term Deposit IncreaseInLongTermDeposit	9000	usd
CY2021	IRME	Increase In Long Term Deposit IncreaseInLongTermDeposit	30000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-59000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-61000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3625000	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3491000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3625000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3491000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-4000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	187000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	949000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2815000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1866000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3002000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2815000	usd
CY2022	IRME	Increase In Right Of Use Assets Against Lease Liability IncreaseInRightOfUseAssetsAgainstLeaseLiability	155000	usd
CY2022	IRME	Increase In Right Of Use Assets Against Long Term Restricted Deposits IncreaseInRightOfUseAssetsAgainstLongTermRestrictedDeposits	19000	usd
CY2021	IRME	Decrease In Trade And Other Payables From Grant Of Options DecreaseInTradeAndOtherPayablesFromGrantOfOptions	45000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zoqmdYq0Mw03" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 - <span id="xdx_826_zoCWmz1Xs4Z5">General</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Business</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IR-Med, Inc. (OTC QB: IRME, hereinafter: the “Parent Company”) was incorporated in Nevada in 2007. IR-Med Inc. was previously named International Display Advertising Inc. and changed its name to IR-Med, Inc. in January 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registered office of IR-Med, Inc. and the corporate headquarters and research facility of IR. Med Ltd. are located in Rosh Pina, Israel. The Parent Company and the Subsidiary are at times collectively referred to as the “Company”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a development stage medical device company developing its technology through its Subsidiary and is utilizing Infra-Red light spectroscopy (IR) combined with Artificial Intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The initial product candidates which are currently in various stages of development are non-invasive, user friendly and designed to address the medical needs of large and growing target patient groups by offering earlier and more accurate information for detection, which is expected to reduce healthcare expenses and reducing the widespread reliance on antibiotics administration, and other interventional options optimizing the delivery of the targeted medical services and, as a result, improving the efficacy and safety of administered treatments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is in its development stage and does not expect to generate significant revenue until such time as the Company shall have completed the design and development of its initial product candidate and obtained the requisite approvals to market the product. During the year ended December 31, 2022, the Company has incurred losses of US$<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20220101__20221231_zc65xq3FUYd1" title="Net losses">4,734</span> thousand and had a negative cash flow from operating activities of US$ <span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20220101__20221231_z95TwKHoP6m2" title="Cash flow from operating activities net">3,375</span> thousand. The accumulated deficit as of December 31, 2022 is US$ <span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20221231_zC4yTuYl9nWd" title="Accumulated deficit">9,930</span> thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management’s plans regarding these matters include continued development and marketing of its products, as well as seeking additional financing arrangements. Between April and July 2022, the Company raised $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20220401__20220731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zgkHKlzpKNMi" title="Raising from private placement">3,625</span> thousand from the private placement of its common stock at a per share price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zfRGUdeffkSl" title="Common stock price per share">0.88</span> and warrants to purchase up to an additional shares of common stock at a per share exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zpcf3ijyzX9h" title="Warrants exercise price per share">1.10</span>. Although management continues to pursue these plans, there is no assurance that the Company will be successful in raising the needed capital from revenues or financing on commercially acceptable terms. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans regarding these matters include continued development and marketing of its products, as well as seeking additional financing arrangements. As a result of the Company’s financial condition substantial doubt exists that the Company will be able to continue as a going concern for one year from the issuance date of this 2022 Annual Report</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IR-Med, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to the Consolidated Financial Statements </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4734000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3375000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9930000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zv6BRRR8Y93d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zR2QbPYu9fUc">Use of Estimates</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant items subject to such estimates and assumptions including fair value of share-based compensation. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>
CY2022	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_z2Gy2n9imsF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zUBNPJq27pO2">Concentrations of credit risks</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Group to concentrations of credit risk consist principally of cash and cash equivalents. Cash and cash equivalents are held in commercial banks in the U.S. and in Israel. Management believes that the financial institution that holds the Group investments have high credit ratings. The Group has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IR-Med, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to the Consolidated Financial Statements </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (Cont’d)</b></span></p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3002000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2815000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1000	usd
CY2022Q4	IRME	Government Institutions GovernmentInstitutions	40000	usd
CY2021Q4	IRME	Government Institutions GovernmentInstitutions	63000	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	3000	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	3000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	55000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	67000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	91000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	41000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	71000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	170000	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	170000	usd
CY2022Q4	IRME	Lessee Operating Lease Incremental Borrowing Yearly Rate LesseeOperatingLeaseIncrementalBorrowingYearlyRate	0.058	pure
CY2022	us-gaap	Increase Decrease In Operating Assets IncreaseDecreaseInOperatingAssets	15000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	155000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	114000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	80000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	40000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	120000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	114000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	65000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	58000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	132000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	140000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	93000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	129000	usd
CY2022Q4	IRME	Accounts Payable Advance From Customers AccountsPayableAdvanceFromCustomers	50000	usd
CY2022Q4	IRME	Accounts Payable Lease Liability AccountsPayableLeaseLiability	74000	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	83000	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	65000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	3000	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	3000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	500000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	395000	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68808970	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68808970	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3525000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	223000	usd
CY2021Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.64
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.64
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	13943842	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	9299547	shares
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1330000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1339000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2021Q4	us-gaap	Share Price SharePrice	0.26
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8277	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.4257	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8277	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.4257	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0018	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.04	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0018	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.017	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Line Of Credit LineOfCredit	40000
CY2021Q4	us-gaap	Line Of Credit LineOfCredit	11000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-41000	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	6000	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	5000	usd
CY2022	IRME	Exchange Rate Loss ExchangeRateLoss	-35000	usd
CY2021	IRME	Exchange Rate Loss ExchangeRateLoss	35000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	28000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4734000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3716000	usd
CY2022	IRME	Weighted Average Number Of Shares Outstanding Basic Beginning WeightedAverageNumberOfSharesOutstandingBasicBeginning	64601649	shares
CY2021	IRME	Weighted Average Number Of Shares Outstanding Basic Beginning WeightedAverageNumberOfSharesOutstandingBasicBeginning	53586023	shares
CY2022	IRME	Effect Of Shares Issued During Period EffectOfSharesIssuedDuringPeriod	2976085	shares
CY2021	IRME	Effect Of Shares Issued During Period EffectOfSharesIssuedDuringPeriod	9524741	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67577734	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63110764	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	27391493	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	16008567	shares
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1118000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	677000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	341000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	218000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	4000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	6000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	26000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1489000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	901000	usd
CY2022Q4	IRME	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	35000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1454000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	901000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1454000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	901000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1454000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	901000	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4569000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2960000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	283000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	80000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	4451000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3636000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4734000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3716000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4734000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3716000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	IRME	Theoretical Tax Benefit TheoreticalTaxBenefit	-994000	usd
CY2021	IRME	Theoretical Tax Benefit TheoreticalTaxBenefit	-780000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	332000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	308000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-89000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-77000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	553000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	580000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	121000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	77000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-31000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	321000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	580000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	901000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	553000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1454000	usd
CY2022Q4	IRME	Accounts Receivables Related Parties Current AccountsReceivablesRelatedPartiesCurrent	2000	usd
CY2021Q4	IRME	Accounts Receivables Related Parties Current AccountsReceivablesRelatedPartiesCurrent	3000	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	60000	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	26000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	7000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	27000	usd
CY2022Q4	IRME	Payroll And Related PayrollAndRelated	16000	usd
CY2021Q4	IRME	Payroll And Related PayrollAndRelated	12000	usd
CY2022Q4	us-gaap	Due To Officers Or Stockholders Current And Noncurrent DueToOfficersOrStockholdersCurrentAndNoncurrent	162000	usd
CY2021Q4	us-gaap	Due To Officers Or Stockholders Current And Noncurrent DueToOfficersOrStockholdersCurrentAndNoncurrent	177000	usd
CY2022	IRME	Subcontractors And Professional Expenses Due To Related Party SubcontractorsAndProfessionalExpensesDueToRelatedParty	461000	usd
CY2021	IRME	Subcontractors And Professional Expenses Due To Related Party SubcontractorsAndProfessionalExpensesDueToRelatedParty	341000	usd
CY2022	IRME	Salaries And Related Expenses Due To Related Party SalariesAndRelatedExpensesDueToRelatedParty	651000	usd
CY2021	IRME	Salaries And Related Expenses Due To Related Party SalariesAndRelatedExpensesDueToRelatedParty	374000	usd
CY2022	IRME	Stock Based Compensation Due To Related Party StockBasedCompensationDueToRelatedParty	1105000	usd
CY2021	IRME	Stock Based Compensation Due To Related Party StockBasedCompensationDueToRelatedParty	794000	usd
CY2022	IRME	Rent And Maintenances RentAndMaintenances	51000	usd
CY2021	IRME	Rent And Maintenances RentAndMaintenances	51000	usd
CY2022	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	6000	usd
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	5000	usd

Files In Submission

Name	View Source	Status
irme-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-009519-index-headers.html	Edgar Link	pending
0001493152-23-009519-index.html	Edgar Link	pending
0001493152-23-009519.txt	Edgar Link	pending
0001493152-23-009519-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
form10-k.htm	Edgar Link	pending
irme-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
irme-20221231_cal.xml	Edgar Link	unprocessable
irme-20221231_def.xml	Edgar Link	unprocessable
irme-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRME
IR-Med, Inc. Stock $irme

2023 Q1 Form 10-K Financial Statement

#000149315223009519 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRME IR-Med, Inc. Stock $irme

2023 Q1 Form 10-K Financial Statement

#000149315223009519 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRME
IR-Med, Inc. Stock $irme